Enanta Pharmaceuticals - Public Comps and Valuation Multiples

Enanta Pharmaceuticals Overview

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Founded

1995

HQ

Employees

120

Website

enanta.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $65.2M

LTM EBITDA -$78.9M

EV

$355M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Enanta Pharmaceuticals Financials

As of November 2025, Enanta Pharmaceuticals reported last 12-month revenue of $65.2M and EBITDA of -$78.9M.

In the same period, Enanta Pharmaceuticals achieved -$81.7M in LTM net income.

See Enanta Pharmaceuticals valuation multiples based on analyst estimates

Enanta Pharmaceuticals P&L

In the most recent fiscal year, Enanta Pharmaceuticals reported revenue of $65.3M and EBITDA of -$71.3M.

Enanta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Enanta Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$65.2M	XXX	$65.3M	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$78.9M	XXX	-$71.3M	XXX	XXX	XXX
EBITDA Margin	-121%	XXX	-109%	XXX	XXX	XXX
EBIT	-$85.8M	XXX	-$85.3M	XXX	XXX	XXX
EBIT Margin	-132%	XXX	-131%	XXX	XXX	XXX
Net Profit	-$81.7M	XXX	-$81.9M	XXX	XXX	XXX
Net Margin	-125%	XXX	-125%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Enanta Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $65.2M. EBITDA for the last twelve months was -$78.9M. In the most recent fiscal year, Enanta Pharmaceuticals achieved $65.3M in revenue and -$71.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$65.2M	Analyst estimates available to subscribers	$65.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$78.9M	Analyst estimates available to subscribers	-$71.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-121.0% EBITDA margin	Analyst estimates available to subscribers	-109.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$85.8M	Analyst estimates available to subscribers	-$85.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-131.6% EBIT margin	Analyst estimates available to subscribers	-130.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$81.7M	Analyst estimates available to subscribers	-$81.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-125.3% net profit margin	Analyst estimates available to subscribers	-125.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Enanta Pharmaceuticals

This financial data table provides comprehensive performance metrics for Enanta Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Enanta Pharmaceuticals generated $65.2M in revenue over the last twelve months.
The company achieved -$78.9M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$81.7M.

Fiscal Year Performance

In the most recent fiscal year, Enanta Pharmaceuticals reported $65.3M in total revenue.
Fiscal year EBITDA was -$71.3M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -109.1%.
Net profit margin reached -125.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Enanta Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals has current market cap of $486M, and EV of $355M.

Market Cap Evolution

Enanta Pharmaceuticals Stock Data

As of December 30, 2025, Enanta Pharmaceuticals's stock price is $17.

See Enanta Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$355M	$486M	XXX	XXX	XXX	XXX	$-3.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Enanta Pharmaceuticals Valuation Multiples

Enanta Pharmaceuticals's trades at 5.3x EV/Revenue multiple, and -3.7x EV/EBITDA.

See valuation multiples for Enanta Pharmaceuticals and 15K+ public comps

Enanta Pharmaceuticals Financial Valuation Multiples

As of December 30, 2025, Enanta Pharmaceuticals has market cap of $486M and EV of $355M.

Equity research analysts estimate Enanta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Enanta Pharmaceuticals has a P/E ratio of -6.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$486M	XXX	$486M	XXX	XXX	XXX
EV (current)	$355M	XXX	$355M	XXX	XXX	XXX
EV/Revenue	5.5x	XXX	5.3x	XXX	XXX	XXX
EV/EBITDA	-4.5x	XXX	-3.7x	XXX	XXX	XXX
EV/EBIT	-4.1x	XXX	-3.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-6.0x	XXX	-4.5x	XXX	XXX	XXX
EV/FCF	-10.3x	XXX	-4.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Enanta Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Enanta Pharmaceuticals Margins & Growth Rates

Enanta Pharmaceuticals's last 12 month revenue growth is -1%

Enanta Pharmaceuticals's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.3M for the same period.

Enanta Pharmaceuticals's rule of 40 is -144% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Enanta Pharmaceuticals's rule of X is -123% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Enanta Pharmaceuticals and other 15K+ public comps

Enanta Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-1%	XXX	-2%	XXX	XXX	XXX
EBITDA Margin	-121%	XXX	-143%	XXX	XXX	XXX
EBITDA Growth	-2%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-144%	XXX	-144%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-123%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	163%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	231%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial